{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:03:00Z","timestamp":1792508580642,"version":"4.5.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,7]]},"DOI":"10.1093\/jnci\/djr418","type":"journal-article","created":{"date-parts":[[2011,10,22]],"date-time":"2011-10-22T04:40:29Z","timestamp":1319258429000},"page":"1799-1806","source":"Crossref","is-referenced-by-count":126,"title":["Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials"],"prefix":"10.1093","volume":"103","author":[{"given":"Liat","family":"Vidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Gafter-Gvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Fang","family":"Hsu Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Pettengell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"issue":"22","key":"key\n\t\t\t\t20170520215055_bib1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2005.04.503","article-title":"Improved survival of follicular lymphoma patients in the United States","volume":"23","author":"Swenson","year":"2005","journal-title":"J Clin Oncol."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib2","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"issue":"3","key":"key\n\t\t\t\t20170520215055_bib3","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20170520215055_bib4","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20170520215055_bib5","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2009.22.7819","article-title":"Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival\u2014A study from the groupe d\u2019etude des lymphomes de l\u2019adulte","volume":"28","author":"Bachy","year":"2010","journal-title":"J Clin Oncol."},{"issue":"4","key":"key\n\t\t\t\t20170520215055_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003805.pub2","article-title":"Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"key\n\t\t\t\t20170520215055_bib7","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3109\/10428191003743460","article-title":"Patterns of survival of follicular lymphomas at a single institution through three decades","volume":"51","author":"Conconi","year":"2010","journal-title":"Leuk Lymphoma."},{"issue":"9759","key":"key\n\t\t\t\t20170520215055_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet."},{"issue":"12","key":"key\n\t\t\t\t20170520215055_bib9","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood."},{"issue":"13","key":"key\n\t\t\t\t20170520215055_bib10","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood."},{"issue":"4","key":"key\n\t\t\t\t20170520215055_bib11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst."},{"key":"key\n\t\t\t\t20170520215055_bib12","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"issue":"5","key":"key\n\t\t\t\t20170520215055_bib13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"24","key":"key\n\t\t\t\t20170520215055_bib14","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med."},{"key":"key\n\t\t\t\t20170520215055_bib15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials."},{"issue":"4","key":"key\n\t\t\t\t20170520215055_bib16","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"key\n\t\t\t\t20170520215055_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib19","article-title":"CNOP vs. CNOP-rituximab vs. rituximab alone as first-line therapy for indolent non-Hodgkin lymphoma (INHL): preliminary results","volume":"102","author":"Baltasar","year":"2003","journal-title":"Blood."},{"issue":"2","key":"key\n\t\t\t\t20170520215055_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ctrv.2006.10.005","article-title":"Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario","volume":"33","author":"Cheung","year":"2007","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"key\n\t\t\t\t20170520215055_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/sonc.2002.32749","article-title":"Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma","volume":"29","author":"Coiffier","year":"2002","journal-title":"Semin Oncol."},{"issue":"7","key":"key\n\t\t\t\t20170520215055_bib22","first-page":"544","article-title":"Overview of Southwest Oncology Group Clinical Trials in non-Hodgkin Lymphoma. S0016. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL","volume":"3","author":"Fisher","year":"2005","journal-title":"Clin Adv Hematol Oncol."},{"issue":"10","key":"key\n\t\t\t\t20170520215055_bib23","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood."},{"issue":"8","key":"key\n\t\t\t\t20170520215055_bib24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ctrv.2005.09.010","article-title":"Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III\/IV follicular lymphoma","volume":"31","author":"Ghielmini","year":"2005","journal-title":"Cancer Treat Rev."},{"key":"key\n\t\t\t\t20170520215055_bib25","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S0145-2126(06)80005-6","article-title":"Patient benefits of maintenance immunotherapy","volume":"30","author":"Ghielmini","year":"2006","journal-title":"Leuk Res."},{"issue":"2","key":"key\n\t\t\t\t20170520215055_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00277-002-0581-1","article-title":"Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab","volume":"82","author":"Herold","year":"2003","journal-title":"Ann Hematol."},{"issue":"15","key":"key\n\t\t\t\t20170520215055_bib27","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol."},{"issue":"1","key":"key\n\t\t\t\t20170520215055_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/sonc.2003.50024","article-title":"Rituximab plus chemotherapy in follicular and mantle cell lymphomas","volume":"30","author":"Hiddemann","year":"2003","journal-title":"Semin Oncol."},{"key":"key\n\t\t\t\t20170520215055_bib29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0145-2126(06)80001-9","article-title":"Rituximab maintenance therapy in follicular lymphoma comes of age","volume":"30","author":"Hiddemann","year":"2006","journal-title":"Leuk Res."},{"issue":"5","key":"key\n\t\t\t\t20170520215055_bib30","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood."},{"issue":"8","key":"key\n\t\t\t\t20170520215055_bib31","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1093\/jnci\/djj156","article-title":"Fourth biannual report of the Cochrane Haematological Malignancies Group","volume":"98","author":"Kober","year":"2006","journal-title":"J Natl Cancer Inst."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.3337.3337","article-title":"Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL)","volume":"108","author":"Lepp\u00e4","year":"2006","journal-title":"Blood."},{"issue":"4","key":"key\n\t\t\t\t20170520215055_bib33","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood."},{"issue":"6","key":"key\n\t\t\t\t20170520215055_bib34","first-page":"37","article-title":"Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma","volume":"27","author":"McLaughlin","year":"2000","journal-title":"Semin Oncol."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib35","first-page":"1472","article-title":"Rituxan delays disease progression in indolent non-Hodgkin's lymphoma","volume":"16","year":"2002","journal-title":"Oncology (Williston Park)."},{"issue":"10","key":"key\n\t\t\t\t20170520215055_bib36","first-page":"1316","article-title":"Rituximab maintenance stretches progression-free survival in patients with indolent NHL","volume":"18","year":"2004","journal-title":"Oncology (Williston Park)."},{"issue":"3\u20134","key":"key\n\t\t\t\t20170520215055_bib37","first-page":"106","article-title":"[Milestone in healing fatal indolent lymphoma]","volume":"42","year":"2004","journal-title":"Krankenpfl J."},{"issue":"4","key":"key\n\t\t\t\t20170520215055_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1349-7006.2006.00173.x","article-title":"Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma","volume":"97","author":"Ogura","year":"2006","journal-title":"Cancer Sci."},{"issue":"1","key":"key\n\t\t\t\t20170520215055_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/sonc.2002.30144","article-title":"Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone","volume":"29","author":"Sarris","year":"2002","journal-title":"Semin Oncol."},{"key":"key\n\t\t\t\t20170520215055_bib40","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0145-2126(06)80004-4","article-title":"Safety of rituximab maintenance therapy in follicular lymphomas","volume":"30","author":"Solal-Celigny","year":"2006","journal-title":"Leuk Res."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4702.4702","article-title":"Maintenance treatment with rituximab in follicular NHL","volume":"108","author":"Rubio-Martinez","year":"2006","journal-title":"Blood."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.2762.2762","article-title":"Induction with fludarabine, cyclophosphamide and rituximab followed by maintenance with rituximab: results of a prospective study in 75 patients (LNHF-03)","volume":"108","author":"Tomas","year":"2006","journal-title":"Blood."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2454.2454","article-title":"Rituximab maintenenance therapy in CD20+ B-Cell non-Hodgkin-lymphoma\u2014first interim results of a prospective randomised phase II study","volume":"106","author":"Witzens-Harig","year":"2005","journal-title":"Blood."},{"issue":"18S","key":"key\n\t\t\t\t20170520215055_bib44","doi-asserted-by":"crossref","first-page":"17524","DOI":"10.1200\/jco.2006.24.18_suppl.17524","article-title":"Rituximab maintenenance therapy in CD20+ B-cell non-Hodgkin lymphoma\u2014Interim results of a multicenter prospective randomised phase II study","volume":"24","author":"Witzens-Harig","year":"2006","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20170520215055_bib45","article-title":"Rituximab maintenenance therapy in CD20+ B-Cell non-Hodgkin-lymphoma\u2014results of a multicenter prospective randomised phase II study","author":"Witzens-Harig"},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib46","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4704.4704","article-title":"Rituximab maintenenance therapy in CD20+ B-Cell non-Hodgkin-lymphoma\u2014results of a multicenter prospective randomised phase II study","volume":"108","author":"Witzens-Harig","year":"2006","journal-title":"Blood."},{"issue":"10","key":"key\n\t\t\t\t20170520215055_bib47","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","article-title":"Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"16","author":"Ghielmini","year":"2005","journal-title":"Ann Oncol."},{"issue":"14S","key":"key\n\t\t\t\t20170520215055_bib48","article-title":"Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)","volume":"22","author":"Hochster","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"key\n\t\t\t\t20170520215055_bib49","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00277-002-0548-2","article-title":"Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial\u2014Intergroup Collaborative Study","volume":"81","author":"Van Oers","year":"2002","journal-title":"Ann Hematol."},{"issue":"6","key":"key\n\t\t\t\t20170520215055_bib50","first-page":"395","article-title":"ECOG 4402: randomized phase III-trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma","volume":"3","author":"Williams","year":"2004","journal-title":"Curr Hematol Rep."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib51","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2967\/jnumed.109.067587","article-title":"Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial","volume":"50","author":"Delaloye","year":"2009","journal-title":"J Nucl Med."},{"issue":"3","key":"key\n\t\t\t\t20170520215055_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma."},{"issue":"3","key":"key\n\t\t\t\t20170520215055_bib53","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3816\/CLM.2008.n.020","article-title":"Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission","volume":"8","author":"Hayslip","year":"2008","journal-title":"Clin Lymphoma Myeloma."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4706.4706","article-title":"A phase IIIb study of rituximab maintenance therapy in patients with follicular non-Hodgkins lymphoma who have responded to induction therapy\u2014MAXIMA-protocol","volume":"108","author":"Hensel","year":"2006","journal-title":"Blood."},{"issue":"9","key":"key\n\t\t\t\t20170520215055_bib55","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/bmt.2008.382","article-title":"Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma","volume":"43","author":"Hicks","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"key\n\t\t\t\t20170520215055_bib56","first-page":"167","article-title":"First results of long term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35\/03","volume":"94","author":"Hitz","year":"2009","journal-title":"Haematologica."},{"issue":"21","key":"key\n\t\t\t\t20170520215055_bib57","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"3","key":"key\n\t\t\t\t20170520215055_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/10428190903503404","article-title":"Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study","volume":"51","author":"Johnston","year":"2010","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"key\n\t\t\t\t20170520215055_bib59","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","article-title":"Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden","volume":"47","author":"Kasteng","year":"2008","journal-title":"Acta Oncol."},{"issue":"1","key":"key\n\t\t\t\t20170520215055_bib60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10428190701704647","article-title":"Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group","volume":"49","author":"Kimby","year":"2008","journal-title":"Leuk Lymphoma."},{"issue":"9","key":"key\n\t\t\t\t20170520215055_bib61","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/cncr.24222","article-title":"Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma","volume":"115","author":"Luminari","year":"2009","journal-title":"Cancer."},{"issue":"1","key":"key\n\t\t\t\t20170520215055_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6605443","article-title":"A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma","volume":"102","author":"Marcus","year":"2010","journal-title":"Br J Cancer."},{"issue":"1","key":"key\n\t\t\t\t20170520215055_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0609.2010.01445.x","article-title":"Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy","volume":"85","author":"McClanahan","year":"2010","journal-title":"Eur J Haematol"},{"issue":"4","key":"key\n\t\t\t\t20170520215055_bib64","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1524-4733.2009.00676.x","article-title":"An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin\u2019s lymphoma in the UK","volume":"13","author":"Ray","year":"2010","journal-title":"Value Health"},{"issue":"13","key":"key\n\t\t\t\t20170520215055_bib65","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood."},{"issue":"21","key":"key\n\t\t\t\t20170520215055_bib66","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol."},{"issue":"1","key":"key\n\t\t\t\t20170520215055_bib67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","article-title":"Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma","volume":"100","author":"Tobinai","year":"2009","journal-title":"Cancer Sci."},{"issue":"11","key":"key\n\t\t\t\t20170520215055_bib68","doi-asserted-by":"crossref","first-page":"189b","DOI":"10.1182\/blood.V110.11.4475.4475","article-title":"The MAXIMA study: safety of rituximab (MabThera\u00ae) maintenance therapy in patients with follicular non-Hodgkins lymphoma who have responded to induction therapy","volume":"110","author":"Wenger","year":"2007","journal-title":"Blood."},{"issue":"21","key":"key\n\t\t\t\t20170520215055_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.6.6","article-title":"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis","volume":"116","author":"Ardeshna","year":"2010","journal-title":"Blood."},{"issue":"6","key":"key\n\t\t\t\t20170520215055_bib70","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2014a randomized phase II trial of the Minnie Pearl Cancer Research Network","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol."},{"issue":"10","key":"key\n\t\t\t\t20170520215055_bib71","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","article-title":"Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study","volume":"27","author":"Hochster","year":"2009","journal-title":"J Clin Oncol."},{"issue":"29","key":"key\n\t\t\t\t20170520215055_bib72","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20170520215055_bib73","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1200\/jco.2010.28.15_suppl.8005","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy","volume":"28","author":"Pettengell","year":"2010","journal-title":"J Clin Oncol."},{"issue":"10","key":"key\n\t\t\t\t20170520215055_bib74","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood."},{"issue":"17","key":"key\n\t\t\t\t20170520215055_bib75","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"van Oers","year":"2010","journal-title":"J Clin Oncol."},{"issue":"22","key":"key\n\t\t\t\t20170520215055_bib76","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.V114.22.1707.1707","article-title":"Rituximab maintenenance therapy in CD20+ B-Cell non-Hodgkin-lymphoma\u2014final results of a multicenter prospective randomised phase II study","volume":"114","author":"Witzens-Harig","year":"2009","journal-title":"Blood."},{"issue":"1","key":"key\n\t\t\t\t20170520215055_bib77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","article-title":"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","volume":"88","author":"Witzens-Harig","year":"2009","journal-title":"Ann Hematol."},{"key":"key\n\t\t\t\t20170520215055_bib78","first-page":"417","article-title":"Brief chemoimmunotherapy rituximab (R)-FND +\/\u2212 R maintenance is effective and safe in newly diagnosed follicular lymhpoma elderly patients: an intergruppo italiano linfomi (IIL) randomized trial","volume":"94","author":"Vitolo","year":"2009","journal-title":"Haematologica."},{"issue":"18S","key":"key\n\t\t\t\t20170520215055_bib79","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/jco.2007.25.18_suppl.8004","article-title":"Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: results from the ECOG\/CALGB intergroup E1496 trial","volume":"25","author":"Hochster","year":"2007","journal-title":"J Clin Oncol."},{"issue":"5","key":"key\n\t\t\t\t20170520215055_bib80","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinternmed.2007.125","article-title":"Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century","volume":"168","author":"Pulte","year":"2008","journal-title":"Arch Intern Med."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/103\/23\/1799\/17311329\/djr418.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:48:33Z","timestamp":1713055713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djr418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,7]]},"references-count":80,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2011,12,7]]},"published-print":{"date-parts":[[2011,12,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djr418","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12,7]]}}}